Johnson & Johnson (JNJ)
| Market Cap | 573.71B +55.6% |
| Revenue (ttm) | 96.36B +5.1% |
| Net Income | 21.04B +71.1% |
| EPS | 8.64 +71.3% |
| Shares Out | 2.41B |
| PE Ratio | 27.60 |
| Forward PE | 20.20 |
| Dividend | $5.36 (2.25%) |
| Ex-Dividend Date | May 26, 2026 |
| Volume | 7,398,894 |
| Open | 240.00 |
| Previous Close | 238.49 |
| Day's Range | 238.14 - 241.60 |
| 52-Week Range | 149.04 - 251.71 |
| Beta | 0.26 |
| Analysts | Buy |
| Price Target | 252.87 (+6.1%) |
| Earnings Date | Jul 15, 2026 |
About JNJ
Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases, and cardiovascular and metabolism distributed through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription... [Read more]
Financial Performance
In 2025, Johnson & Johnson's revenue was $94.19 billion, an increase of 6.05% compared to the previous year's $88.82 billion. Earnings were $26.80 billion, an increase of 90.56%.
Financial StatementsAnalyst Summary
According to 24 analysts, the average rating for JNJ stock is "Buy." The 12-month stock price target is $252.87, which is an increase of 6.10% from the latest price.
News
Johnson & Johnson expands U.S. availability of TECNIS PureSee IOL
Johnson & Johnson is expanding the U.S. roll-out of its latest advancement in presbyopia-correcting intraocular lenses. TECNIS PureSee IOL is an extended depth of focus lens designed to support visual...
Johnson & Johnson Expands U.S. Availability of TECNIS PureSee IOL, an Advanced Lens Option for Cataract Surgeons and Patients
JACKSONVILLE, Fla.--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) is expanding the U.S. roll-out of its latest advancement in presbyopia-correcting intraocular lenses (PC-IOLs). TECNIS PureSee IOL is...
Healthcare ETFs: From Broad Exposure to Big Breakthroughs
With AI and space dominating many of the market's most popular investment themes, it can be difficult to find differentiated opportunities. Healthcare is often viewed as one of the more defensive sect...
Johnson & Johnson presents first results from ENERGY study
Johnson & Johnson presented the first results from the Phase 2/3 ENERGY study showing that Imaavy produced a statistically significant durable hemoglobin, or Hgb, response with rapid onset of effect…
IMAAVY® (nipocalimab-aahu) demonstrates durable hemoglobin response and rapid onset of effect in pivotal Phase 2/3 study in warm autoimmune hemolytic anemia (wAIHA), an autoantibody-driven disease with no FDA-approved therapies
Patients in the IMAAVY 30 mg/kg treatment group a achieved statistically significant durable hemoglobin response b , with mean hemoglobin improvement of at least 1 g/dL as early as Week 1 c More pat...
Johnson & Johnson Hit with $32 Million Verdict in Los Angeles Asbestos Trial
LOS ANGELES--(BUSINESS WIRE)-- #JohnsonJohnson--A Los Angeles jury has awarded $32 million to the family of a California woman who died from pleural mesothelioma after years of exposure to an asbestos...
Johnson & Johnson CEO Says Cure for Certain Cancers Is Realistic Goal
Joaquin Duato said finding a cure for certain cancers and turning others into chronic diseases is an achievable target for the coming decade.
Johnson & Johnson Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026
Strong growth continues with double-digit gains across key products and new launches in immunology and oncology. TREMFYA and ICOTYDE drive immunology momentum, while RYBREVANT, ERLEADA, and INLEXZO expand oncology opportunities. Neuroscience and cardiovascular assets show robust progress.
Johnson & Johnson to Buy Firefly Bio for $1 Billion
Johnson & Johnson has agreed to buy biotechnology company Firefly Bio for $1 billion in cash in a deal that bolsters the drugmaker's oncology pipeline.
M&A News: Johnson & Johnson (JNJ) Reaches a Massive $1B Deal for Firefly Bio to Expand Its Oncology Pipeline
Johnson & Johnson stock was a hot topic on Monday after the company announced a $1 billion deal.
Johnson & Johnson to acquire Firefly Bio for $1B in cash
Johnson & Johnson entered into a definitive agreement to acquire Firefly Bio, Inc., a biotechnology company advancing its proprietary Firelink degrader antibody conjugate platform, for $1B in cash. Th...
Johnson & Johnson to buy Firefly Bio for $1 billion
Johnson & Johnson said on Monday it will acquire biotech Firefly Bio for $1 billion in cash, as it looks to expand its cancer drug pipeline.
Johnson & Johnson to Acquire Firefly Bio, Inc. to Expand Oncology Pipeline with Novel Degrader Antibody Conjugate Platform
NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) today announced it has entered into a definitive agreement to acquire Firefly Bio, Inc., a biotechnology company advancing its propr...
J&J beats lawsuit alleging that talc caused three women's cancer
A Los Angeles jury on Friday sided with Johnson & Johnson in a lawsuit by the families of three women who alleged that the company's talc products caused ovarian cancer, finding that J&J was not neg...
Johnson & Johnson presents exploratory analyses from DAHLIAS study
Johnson & Johnson announced new biomarker exploratory analyses from the Phase 2 DAHLIAS study evaluating nipocalimab in adults with moderate-to-severe Sjogren’s disease showing that participants with ...
Johnson & Johnson announces nipocalimab met primary endpoint in JASMINE study
Johnson & Johnson announced nipocalimab met the primary endpoint of decreasing disease activity at 24 weeks as measured by SLE Responder Index 4 and continued to demonstrate sustained reduction in…
Johnson & Johnson late-breaking results show nipocalimab significantly reduced systemic lupus erythematosus (SLE) disease activity in a Phase 2 study
Nipocalimab – the first and only neonatal Fc receptor (FcRn) blocker to be studied in systemic lupus erythematosus – is designed to target and reduce pathogenic immunoglobulin G (IgG) autoantibodies a...
Johnson & Johnson presents new data further reinforcing the role of nipocalimab in lowering the autoantibodies driving Sjögren's disease
Nipocalimab, an immunoselective neonatal Fc receptor (FcRn) blocker, is designed to target and reduce pathogenic immunoglobulin G (IgG) autoantibodies associated with Sjögren's disease while preservin...
Jim Cramer says look to buy these 5 stocks outside the AI trade for diversification
CNBC's Jim Cramer said investors should consider adding exposure to out-of-favor sectors if investors begin rotating away from high-flying technology stocks. He highlighted JPMorgan, Johnson & Johnson...
Johnson & Johnson announces Phase 3 Proteus study met primary endpoints
Johnson & Johnson announced results from the final analysis of the Phase 3 Proteus study showing the investigational use of apalutamide plus hormone therapy, given for six months before and…
Johnson & Johnson announces results from Phase 1b/2 OrigAMI-4 study
Johnson & Johnson announced results from the Phase 1b/2 OrigAMI-4 study showing that subcutaneous amivantamab and hyaluronidase-lpuj delivered durable responses in patients with advanced head and neck...
Johnson & Johnson's Phase 3 prostate cancer study shows ERLEADA® (apalutamide) before and after surgery significantly reduces risk of metastasis or death, versus hormone therapy alone, potentially shifting a decades-long treatment paradigm
Compared with patients receiving hormone therapy alone, patients were nine times more likely to have little to no cancer remaining in the prostate after surgery, with a 20 percent reduction in the ris...
RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) pivotal data show strong and durable responses in advanced head and neck cancer where options remain limited
More than one-third of responders with previously treated disease achieved complete responses, with median duration of response not yet reached, as reported in new Journal of Clinical Oncology publica...
Johnson & Johnson's Phase 3 prostate cancer study shows ERLEADA® (apalutamide) before and after surgery significantly reduces risk of metastasis or death, breaking a decades-long treatment paradigm
Patients were nine times more likely to have little to no cancer remaining in the prostate after surgery, with a 20% reduction in the risk of developing metastasis or death Data selected to open the ...